100578-79-8
100578-79-8
Chemical Structure
Verapamil-d7
Synonym(s): (±)-Verapamil-d7; CP-16533-1-d7
- CAS No.: 100578-79-8
- Formula:C27H31D7N2O4
- Molecular Weight:461.64
InChIKey: SGTNSNPWRIOYBX-ZGBMZCDDSA-N
SMILES: [2H]C(C(CCCN(CCC1=CC(OC)=C(C=C1)OC)C)(C2=CC(OC)=C(C=C2)OC)C#N)(C([2H])([2H])[2H])C([2H])([2H])[2H]
Biological Activity: Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Verapamil-d7 | Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil (Standard) | 99.72% | Verapamil (Standard) is the analytical standard of Verapamil. This product is intended for research and analytical applications. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Verapamil-d7 (hydrochloride) | (Rac)-Verapamil-d7 (hydrochloride) is the deuterium labeled (Rac)-Verapamil. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d3 | Verapamil-d3 ((±)-Verapamil-d3) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d6 | Verapamil-d6 ((±)-Verapamil-d6) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil | 99.88% | Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25(3):743-746. [Content Brief]
- [2]. Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S. [Content Brief]
- [3]. Rehnqvist N,et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996 Jan;17(1):76-81. [Content Brief]
